AZD-2563 AstraZeneca.
Copyright policy )AZD-2563 AstraZeneca.
AstraZeneca is developing AZD-2563, an oxazolidinone with a novel mechanism of action, for the potential treatment of gram-positive bacterial infections, including those caused by multidrug-resistant strains [349551], [399542]. As of December 2001, AZD-2563 had completed an escalating-dose phase I trial in the UK and was being developed in the US [433897]; at this time, AstraZeneca did not expect launch until after 2004 [431673]. In October 2001, Morgan Stanley estimated launch in 2004 with sales of US $20 million in that year, rising to US $46 million in following years [429700].
Disease Models, Animal, Structure-Activity Relationship, Acetamides, Linezolid, Animals, Microbial Sensitivity Tests, Gram-Positive Bacteria, Gram-Positive Bacterial Infections, Oxazolidinones, Anti-Bacterial Agents
Disease Models, Animal, Structure-Activity Relationship, Acetamides, Linezolid, Animals, Microbial Sensitivity Tests, Gram-Positive Bacteria, Gram-Positive Bacterial Infections, Oxazolidinones, Anti-Bacterial Agents
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!